NCCN Guidelines for Patients® | Esophageal Cancer - page 76

76
NCCN Guidelines for Patients
®
: Esophageal Cancer
Version 1.2013
Part 6: Adenocarcinomas
First-line regimens
Preferred
Trastuzumab and cisplatin and fluoropyrimidine (5-FU or capecitabine)
Trastuzumab and other chemotherapy regimens that don’t include epirubicin
Docetaxel, cisplatin, and 5-FU
Docetaxel, carboplatin, and 5-FU
Docetaxel, oxaliplatin, and 5-FU
Epirubicin, cisplatin, and 5-FU
Epirubicin, oxaliplatin, and 5-FU
Epirubicin, cisplatin, and capecitabine
Epirubicin, oxaliplatin, and capecitabine
Fluoropyrimidine (5-FU or capecitabine) and cisplatin
Fluoropyrimidine (5-FU or capecitabine) and oxaliplatin
5-FU and irinotecan
Other
Paclitaxel with cisplatin or carboplatin
Docetaxel with cisplatin
Docetaxel and irinotecan
Fluoropyrimidine (5-FU or capecitabine)
Docetaxel
Paclitaxel
1...,66,67,68,69,70,71,72,73,74,75 77,78,79,80,81,82,83,84,85,86,...100
Powered by FlippingBook